ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology firm focused on developing innovative cancer therapies, has announced its participation in several prominent investor conferences in Q1 2026. The company's leadership will engage with investors at the Wells Fargo Executive Biotech Summit, the TD Cowen 46th Annual Health Care Conference, and the UBS Biotech Summit, highlighting its commitment to transparency and stakeholder engagement.

The schedule begins with one-on-one meetings at the Wells Fargo Executive Biotech Summit, running from February 24-25, 2026, in Lake Tahoe, California. Following this, ALX Oncology will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 AM EST in Boston, Massachusetts. Investors can access the presentation via a webcast available on the company's official website. A replay of the event will be archived for 90 days post-presentation, allowing broader access for those unable to attend live.

The final event in this series is set for March 10, 2026, where ALX Oncology will again participate in one-on-one meetings at the UBS Biotech Summit in Miami, Florida.

ALX Oncology is making significant strides in the oncology space, particularly with its lead candidate, evorpacept. Currently investigated in multiple clinical trials, evorpacept shows promise as a foundational treatment in immuno-oncology. Additionally, the company is advancing its second candidate, ALX2004, an EGFR-targeted antibody-drug conjugate, which is undergoing a Phase 1 dose-escalation trial for solid tumors expressing EGFR.

For further details, stakeholders can visit ALX Oncology’s website or connect through their LinkedIn page.

As ALX Oncology prepares for a series of significant investor conferences in Q1 2026, it is crucial for stakeholders to consider the implications of the company’s participation and the potential impact on market sentiment and stock performance. ALX Oncology, which specializes in novel cancer therapeutics, has positioned itself at the forefront of immuno-oncology with its promising lead candidate, evorpacept, currently under evaluation in various clinical trials.

The upcoming presentations at the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit provide a strategic opportunity for ALX to showcase its advancements and shed light on its pipeline of therapies, including the innovative ALX2004. Investors should monitor these events closely, as management's insights could provide critical information regarding trial results, regulatory timelines, and potential commercialization strategies.

Given the inherent volatility in the biotech sector, market participants should brace for possible fluctuations in ALX’s stock price in response to remarks made during these conferences. Successful articulation of the company’s value proposition, alongside evidence of robust clinical data, could bolster investor confidence and enhance stock valuations. Conversely, any ambiguity or negative data could pose risks.

It is advisable for investors to maintain a watchful eye on announcements stemming from these conferences, especially regarding enrollment in clinical trials and data analytics regarding evorpacept and ALX2004. As with all biotech investments, risk management through diversified portfolios and an awareness of market trends will be essential.

In conclusion, ALX Oncology offers a compelling opportunity but remains subject to typical biotech uncertainties. Engaging with these investor events could yield significant insights for those seeking to navigate their investment stakes effectively.